Literature DB >> 19756467

[Therapy of benign prostate syndrome (BPS): guidelines of the German Urologists (DGU)].

R Berges1, K Dreikorn, K Höfner, S Madersbacher, M C Michel, R Muschter, M Oelke, O Reich, W Rulf, C Tschuschke, U Tunn.   

Abstract

Entities:  

Mesh：

Year:  2009        PMID： 19756467     DOI： 10.1007/s00120-009-2067-4

Source DB:  PubMed          Journal:  Urologe A        ISSN： 0340-2592            Impact factor:   0.639


× No keyword cloud information.
  228 in total

1.  Transurethral water-induced thermotherapy for the treatment of benign prostatic hyperplasia: a prospective multicenter clinical trial.

Authors:  R Muschter; I Schorsch; L Danielli; C Russel; A Timoney; D Yachia; E Jolkowsky; G Matalon; T Roder; J Nordling
Journal:  J Urol       Date:  2000-11       Impact factor: 7.450

2.  Laparoscopic retropubic simple prostatectomy.

Authors:  René Sotelo; Massimiliano Spaliviero; Alejandro Garcia-Segui; Waleed Hasan; John Novoa; Mihir M Desai; Jihad H Kaouk; Inderbir S Gill
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

3.  Improvement of pressure flow parameters with finasteride is greater in men with large prostates. Finasteride Urodynamics Study Group.

Authors:  P Abrams; W Schäfer; T L Tammela; D M Barrett; H Hedlund; H J Rollema; A Matos-Ferreira; J Nordling; R Bruskewitz; J T Andersen; T Hald; P Miller; R Kirby; S Mustonen; A Cannon; C A Jacobsen; G J Gormley; M P Malice; M A Bach
Journal:  J Urol       Date:  1999-05       Impact factor: 7.450

4.  Clinical predictors in the use of finasteride for control of gross hematuria due to benign prostatic hyperplasia.

Authors:  Michael C Kearney; Jonathan B Bingham; Ryan Bergland; Patricia Meade-D'Alisera; Peter J Puchner
Journal:  J Urol       Date:  2002-06       Impact factor: 7.450

5.  Effect of finasteride, a 5 alpha-reductase inhibitor on prostate tissue androgens and prostate-specific antigen.

Authors:  J Geller
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

6.  Holmium laser resection v transurethral resection of the prostate: results of a randomized trial with 2 years of follow-up.

Authors:  P J Gilling; K M Kennett; M R Fraundorfer
Journal:  J Endourol       Date:  2000-11       Impact factor: 2.942

7.  Photoselective vaporization (PVP) versus transurethral resection of the prostate (TURP): a prospective bi-centre study of perioperative morbidity and early functional outcome.

Authors:  Alexander Bachmann; Leander Schürch; Robin Ruszat; Stephen F Wyler; Hans-Helge Seifert; Alexander Müller; Kurt Lehmann; Tullio Sulser
Journal:  Eur Urol       Date:  2005-07-18       Impact factor: 20.096

8.  Randomised, placebo-controlled, double-blind clinical trial of beta-sitosterol in patients with benign prostatic hyperplasia. Beta-sitosterol Study Group.

Authors:  R R Berges; J Windeler; H J Trampisch; T Senge
Journal:  Lancet       Date:  1995-06-17       Impact factor: 79.321

9.  Transurethral needle ablation versus transurethral resection of the prostate for the treatment of symptomatic benign prostatic hyperplasia: 5-year results of a prospective, randomized, multicenter clinical trial.

Authors:  Brian Hill; William Belville; Reginald Bruskewitz; Muta Issa; Ramon Perez-Marrero; Claus Roehrborn; Martha Terris; Michael Naslund
Journal:  J Urol       Date:  2004-06       Impact factor: 7.450

10.  Inhibitory effects of Serenoa repens on the kinetic of pig prostatic microsomal 5alpha-reductase activity.

Authors:  M F Palin; M Faguy; J G LeHoux; G Pelletier
Journal:  Endocrine       Date:  1998-08       Impact factor: 3.925
View more
  10 in total

1.  [S2e guideline of the German urologists: Conservative and pharmacologic treatment of benign prostatic hyperplasia].

Authors:  K Höfner; T Bach; R Berges; K Dreikorn; C Gratzke; S Madersbacher; M-S Michel; R Muschter; M Oelke; O Reich; C Tschuschke; T Bschleipfer
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

2.  [S2e guideline of the German urologists: Instrumental treatment of benign prostatic hyperplasia].

Authors:  T Bschleipfer; T Bach; R Berges; K Dreikorn; C Gratzke; S Madersbacher; M-S Michel; R Muschter; M Oelke; O Reich; C Tschuschke; K Höfner
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

Review 3.  [Surgical treatment of male lower urinary tract symptoms (LUTS)].

Authors:  C Gratzke; F Strittmatter; O Reich; A Bachmann; C G Stief; M Seitz
Journal:  Urologe A       Date:  2012-09       Impact factor: 0.639

Review 4.  [Importance of adrenoceptor blockers and alpha reductase inhibitors : Monotherapy for treatment of benign prostate syndrome].

Authors:  F Strittmatter; S Madersbacher; C G Stief; C Gratzke
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

5.  [UroLift®: an operative non-ablative procedure for treatment of benign prostatic syndrome].

Authors:  R Berges; K D Sievert; C Gratzke; U Wetterauer
Journal:  Urologe A       Date:  2013-03       Impact factor: 0.639

6.  [Phytotherapy of benign prostate syndrome and prostate cancer: better than placebo].

Authors:  C Wehrberger; K Dreikorn; B J Schmitz-Dräger; M Oelke; S Madersbacher
Journal:  Urologe A       Date:  2012-12       Impact factor: 0.639

7.  [Medical therapy of lower urinary tract symptoms [corrected]].

Authors:  F Strittmatter; S Madersbacher; C G Stief; C Gratzke
Journal:  Urologe A       Date:  2012-08       Impact factor: 0.639

8.  Fixed-dose combination PRO 160/120 of sabal and urtica extracts improves nocturia in men with LUTS suggestive of BPH: re-evaluation of four controlled clinical studies.

Authors:  Matthias Oelke; Richard Berges; Sandra Schläfke; Martin Burkart
Journal:  World J Urol       Date:  2014-06-18       Impact factor: 4.226

Review 9.  [Combination therapy of benign prostate syndrome/lower urinary tract symptoms].

Authors:  S Madersbacher
Journal:  Urologe A       Date:  2013-02       Impact factor: 0.639

10.  [Urinary incontinence in the elderly: what can and should be done?].

Authors:  B Amend; S Kruck; J Bedke; R Ritter; L Arenas da Silva; C Chapple; A Stenzl; K-D Sievert
Journal:  Urologe A       Date:  2013-06       Impact factor: 0.639
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.